SBIR Topic 97 - Minimally Invasive Test for Chemotherapy-induced Cardiotoxicity - Phase I

SBIR 主题 97 - 化疗引起的心脏毒性的微创测试 - I 期

• 批准号: 9365914
• 负责人: ALBERTO GANDINI
• 金额: $ 21.26万
• 依托单位: ACCEL DIAGNOSTICS, LLC
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-08-10 至 2017-08-09
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9365914
• 关键词: Biological Markers; Cancer Survivor; Cardiac; Cardiotoxicity; Cardiovascular system; Chemotherapy-Oncologic Procedure; Complication; Detection; Development; Disease; Early Diagnosis; Echocardiography; Effectiveness; Frequencies; Funding; Goals; Heart failure; Image; Imaging technology; Industry; Injury; Malignant Neoplasms; Metabolism; Methods; Molecular; Monitor; Morbidity - disease rate; Myocardial; Myocardial dysfunction; Patients; Phase; Positron-Emission Tomography; Reporting; Research; Resolution; Safety; Small Business Innovation Research Grant; Structure; Technology; Testing; Therapeutic; Tissues; Toxicant exposure; Treatment Efficacy; Ultrasonography; United States Food and Drug Administration; Validation; base; cancer therapy; chemotherapy; design; functional decline; imaging modality; imaging probe; improved; in vivo; innovation; method development; minimally invasive; mortality; novel; novel therapeutics; phase change; pre-clinical

Cardiotoxicity is increasingly recognized as a significant challenge to many existing therapies and as a potential barrier to the development of new therapies. For example, despite improved survival from cancer, chemotherapy-induced cardiotoxicity has emerged as a significant problem. Cardiovascular complication, particularly heart failure, is an important cause of morbidity and mortality among cancer survivors. In small studies, cardioprotective strategies against cancer therapy-induced cardiac dysfunction are effective if implemented early at the subclinical phase. However, detection of the frequency of subclinical disease and subsequent ability to protect against further functional decline are limited by inadequacy of current technologies to accurately assess and monitor changes in cardiac structure and function. Novel non-invasive strategies that detect early subclinical changes in cardiac structure, function, and/or tissue are needed to improve detection and monitoring of cardiac injury in order to improve cardioprotection and effectiveness of cancer therapeutics or other toxic exposure. Studies that demonstrate increased sensitivity and precision of existing or enhanced imaging technologies with respect to normal and altered cardiac structure, function, energetics, and metabolism are sought. Pre-clinical or patient studies using molecular changes or biomarkers to enhance early detection of cardiac derangements are also responsive.

人们越来越认识到心脏毒性是对许多现有疗法的重大挑战，也是开发新疗法的潜在障碍。 例如，尽管癌症生存率有所提高，但化疗引起的心脏毒性已成为一个重大问题。 心血管并发症，特别是心力衰竭，是癌症幸存者发病和死亡的重要原因。 在小型研究中，如果在亚临床阶段早期实施，针对癌症治疗引起的心功能障碍的心脏保护策略是有效的。 然而，由于当前技术不足以准确评估和监测心脏结构和功能的变化，对亚临床疾病频率的检测以及随后防止功能进一步下降的能力受到限制。 需要新的非侵入性策略来检测心脏结构、功能和/或组织的早期亚临床变化，以改善心脏损伤的检测和监测，从而改善心脏保护和癌症治疗或其他有毒物质暴露的有效性。 寻求证明现有或增强的成像技术对于正常和改变的心脏结构、功能、能量和代谢的敏感性和精确度有所提高的研究。 使用分子变化或生物标志物来增强心脏紊乱的早期检测的临床前或患者研究也有反应。